Celldex Email Format
Biotechnology ResearchNew Jersey, United States201-500 Employees
Celldex is a biotechnology research company based in Hampton, New Jersey, with 201-500 employees and a website at https://celldex.com. The company focuses on immunology, developing novel antibody-based therapies that engage the human immune system to address allergic, inflammatory, and autoimmune disorders. Its mast cell-targeting pipeline includes barzolvolimab for conditions such as chronic urticaria and angioedema, and CDX-622, a bispecific antibody targeting soluble SCF and TSLP. In 2026, Celldex reported Phase 2 results for barzolvolimab showing rapid and durable improvements in angioedema for CSU patients and Phase 1 results for CDX-622 demonstrating rapid, durable, dose-dependent reductions in serum tryptase, indicating mast cell depletion, with CDX-622 being well tolerated across tested dose levels. The company has presented multiple sessions at the European Academy of Allergy and Clinical Immunology Annual Congress in 2026, and its development activities include a Phase 3 CSU program and a Phase 1b study of CDX-622 in asthma.